The People Behind the Counsel

Aubrey Poppleton serves as Regulatory Attorney at THE FDA LAW SOLUTION LLC, advising clients on compounding pharmacy regulation, multistate licensure, and FDA/FTC compliance across the food, cosmetics, dietary supplement, and life sciences sectors.

Aubrey's practice brings a comprehensive command of the pharmacy regulatory lifecycle, from facility conception through ongoing operation. Her practice encompasses multistate and nonresident pharmacy licensure across divergent state regulatory schemes; 503A pharmacy and 503B outsourcing facility compliance, including USP sterile and nonsterile compounding standards; facility design and controlled substances requirements; and pre-licensure and pre-inspection consulting for compounding pharmacy operations entering new markets or preparing for regulatory scrutiny. Her experience also extends to constructing and building out of medical and pharmacy facilities, directing projects from initial design to ensure alignment with state board and compounding standards. She further advises on the distribution and shipping obligations, labeling requirements, and advertising claims review that govern pharmacy and compounded products in the marketplace.

Beyond pharmacy practice, Aubrey counsels clients on labeling and claims substantiation, advertising review, and enforcement risk under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulations, including Dietary Supplement Health and Education Act (DSHEA), the Nutrition Labeling and Education Act (NLEA), the Food Safety Modernization Act (FSMA), and the Modernization of Cosmetics Regulation Act (MoCRA), as well as dietary supplement cGMP requirements (21 C.F.R. Part 111), food labeling obligations (21 C.F.R. Part 101), and FTC advertising standards, which frequently intersect with FDA-regulated claims.

Aubrey is particularly relied upon to help clients navigate enforcement risk before it escalates, conducting proactive reviews of labeling, marketing claims, and manufacturing practices to surface exposure early and advising on corrective measures. When clients do receive a Warning Letter, Untitled Letter, or import alert, she guides them through the response process: analyzing the cited violations, coordinating corrective action plans, and helping shape the written response FDA expects within its standard timeframe. Her approach treats a Warning Letter not as an isolated event but as a signal to reassess broader compliance systems, so clients can resolve the immediate issue while reducing the likelihood of recurrence or escalation to a seizure, an injunction, or a consent decree.

Aubrey's regulatory instincts are informed by her prior experience in civil litigation and tenure with the U.S. House Committee on Energy and Commerce, which authorizes and oversees the FDA. That background gives her a litigator's eye for early risk detection, risk mitigation, and a firsthand understanding of the policy considerations behind FDA enforcement.

In addition to her regulatory counseling responsibilities, Aubrey oversees the firm's operations, developing and implementing systems that support efficient practice management and client engagement.

Aubrey earned her Juris Doctor from The Catholic University of America, Columbus School of Law, and her Bachelor of Arts in Government from the University of Maryland, College Park. She is admitted to practice law in Georgia and Maryland.

Aaliyah Alexander is a Law Clerk at The FDA Law Solution, where she focuses on FDA regulatory and compliance matters involving food, cosmetics, dietary supplements, hemp-derived products, and cannabinoid regulation. She has developed a particular interest in the rapidly evolving regulatory landscape surrounding hemp, THC, CBD, and other cannabinoid-containing products, with an emphasis on helping businesses understand how emerging federal and state requirements affect product development, marketing, and distribution.

Recent legislative and regulatory developments, including Public Law 119-37 and evolving federal and state hemp regulations, have drawn Aaliyah's attention to the intersection of FDA regulation, state cannabis laws, and consumer product compliance. As a result, she has taken a proactive approach to helping clients understand new regulatory requirements through practical, business-focused guidance while identifying potential compliance risks before they become enforcement issues.

Aaliyah has begun assisting with questions concerning the impact of these regulatory changes on product formulation, labeling, marketing claims, interstate distribution, retail sales, and the classification of hemp-derived consumer products. She believes the evolving regulatory framework will have its greatest impact on manufacturers, brand owners, distributors, and retailers operating in the hemp, CBD, THC, dietary supplement, cosmetic, and functional food industries as both federal and state oversight continue to expand.

In addition, Aaliyah has a particular interest in FDA “General Wellness” policies and helps clients evaluate when products and promotional claims may fall within the FDA's General Wellness guidance and when they may instead trigger regulation as drugs, dietary supplements, cosmetics, or medical devices. She works with clients to assess product claims, advertising language, labeling, and marketing strategies to reduce regulatory risk while positioning products for commercial success.

Aaliyah is committed to providing practical, forward-looking regulatory guidance that enables businesses to anticipate regulatory change, maintain compliance, and confidently bring innovative consumer products to market.